Disease Overview：Renal amyloidosis（RA）
Renal amyloidosis is a rare systemic disorder characterized by the extracellular deposition of misfolded amyloid fibrils—primarily immunoglobulin light chains (AL type) or serum amyloid A protein (AA type)—in the glomeruli, interstitium, and vasculature of the kidneys. These deposits disrupt normal renal architecture and function, leading to progressive proteinuria, nephrotic syndrome, and ultimately chronic kidney disease or end-stage renal failure. Diagnosis requires renal biopsy with Congo red staining and polarized light microscopy, supplemented by mass spectrometry or immunohistochemistry for precise typing. Prognosis varies significantly by subtype: AL amyloidosis carries high morbidity due to concurrent cardiac involvement, while AA amyloidosis often reflects underlying chronic inflammatory conditions. Early detection and subtype-specific therapy—such as autologous stem cell transplantation with high-dose melphalan for AL, or anti-inflammatory biologics for AA—are critical to preserving renal function and improving survival.
China offers distinct advantages in managing renal amyloidosis. Leading nephrology centers—including Peking University First Hospital and Shanghai Renji Hospital—house multidisciplinary amyloidosis programs with internationally trained specialists, advanced diagnostic platforms (e.g., laser microdissection coupled with LC-MS/MS), and access to novel therapeutics approved earlier than in many Western markets. Clinical outcomes align with global benchmarks: over 70% of AL patients achieve hematologic response within six months, and renal function stabilization is observed in 60–65% of carefully selected cases. Treatment costs in China are typically 40–60% lower than in the US or EU, without compromising quality—drugs, diagnostics, and hospital stays remain rigorously standardized under NMPA oversight. As a dedicated medical tourism agency, we facilitate seamless care for international patients: coordinating appointments with top-tier nephrologists, verifying treatment protocols, providing itemized, transparent pricing in advance, and offering end-to-end support—from visa assistance and accommodation to real-time clinical translation and post-discharge follow-up coordination.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown for Renal Amyloidosis (Nephrology Department)
I. Non-Surgical / Conservative / Medication-Based Therapy *Target Criteria:* Early-stage AL amyloidosis (serum free light chain abnormality confirmed), preserved eGFR (>30 mL/min/1.73m²), no cardiac involvement (NT-proBNP <1,800 ng/L, echocardiogram normal).
- •Chemotherapy Regimen (Bortezomib–Dexamethasone–Cyclophosphamide)
• Bortezomib (IV, 1.3 mg/m² × 8 doses): $2,100 • Dexamethasone (oral, 40 mg weekly): $120 • Cyclophosphamide (oral, 50 mg/day): $180 • Monitoring labs (serum FLC, creatinine, CBC, LFTs × 12): $480 • Renal biopsy (repeat at 3 months if indicated): $320
- •Supportive Care (Ongoing)
• Diuretics (furosemide 40 mg bid): $24/year • Albumin infusion (if serum albumin <2.5 g/dL, 10 g weekly × 4 weeks): $240
II. Procedural / Interventional Options *Eligibility Criteria:* Confirmed AL subtype, hematologic response required pre-transplant; eGFR <15 mL/min/1.73m² or dialysis-dependent; no active infection or uncontrolled heart failure.
- •Autologous Stem Cell Transplant (ASCT)
• Mobilization (G-CSF + plerixafor), apheresis, cryopreservation: $2,600 • Conditioning (melphalan 200 mg/m² IV): $1,100 • Inpatient transplant & 30-day monitoring (Grade 3A hospital, ICU-capable nephrology ward): $8,400 • Total procedure range: $12,000–$14,500
- •Kidney Transplant (De Novo or Post-ASCT)
• Surgery + 14-day inpatient stay (nephrology-led perioperative care): $16,200 • Induction immunosuppression (anti-thymocyte globulin + tacrolimus): $1,800 • *Note:* Only considered after ≥6-month hematologic remission and negative bone marrow biopsy.
III. Special/Complex Condition Management
- •Dialysis-dependent AL with Cardiac Involvement (NYHA III–IV):
- •AA Amyloidosis (Secondary to chronic inflammation):
Quick Selection Guide
- •<65 years, fit, AL subtype, no cardiac involvement: ASCT is first-line — optimal long-term renal survival ($13,200 median)
- •≥65 years or frail, AL with mild proteinuria (<3 g/day): Oral chemotherapy (CyBorD) — cost-effective, lower toxicity ($4,900)
- •AA amyloidosis with active rheumatoid arthritis: Tocilizumab + NSAID control — targets root cause ($3,860)
- •ESRD + failed ASCT or ineligible: Kidney transplant post-remission ($17,500 total)
- •Limited budget (<$3,000): Supportive care + low-dose melphalan (off-label, $850/year) — palliative focus
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Renal amyloidosis Medical Vacation Packages
Curated transparent all-inclusive packages combining Renal amyloidosis treatment with China top medical destinations:
